These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20616021)

  • 1. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands.
    Lindzen M; Lavi S; Leitner O; Yarden Y
    Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12559-63. PubMed ID: 20616021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
    Rabia E; Garambois V; Hubert J; Bruciamacchie M; Pirot N; Delpech H; Broyon M; Theillet C; Colombo PE; Vie N; Tosi D; Gongora C; Khellaf L; Jarlier M; Radosevic-Robin N; Chardès T; Pèlegrin A; Larbouret C
    MAbs; 2021; 13(1):1914883. PubMed ID: 33876707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF.
    Sato S; Drake AW; Tsuji I; Fan J
    PLoS One; 2012; 7(12):e51964. PubMed ID: 23251664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
    Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
    J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
    Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
    Modjtahedi H; Dean C
    Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.
    Modjtahedi H; Eccles SA; Box G; Styles J; Dean CJ
    Cell Biophys; 1993; 22(1-3):129-46. PubMed ID: 7534211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
    Modjtahedi H; Styles JM; Dean CJ
    Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.
    Riese DJ; Kim ED; Elenius K; Buckley S; Klagsbrun M; Plowman GD; Stern DF
    J Biol Chem; 1996 Aug; 271(33):20047-52. PubMed ID: 8702723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
    Modjtahedi H; Komurasaki T; Toyoda H; Dean C
    Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo.
    Nickerson NK; Mill CP; Wu HJ; Riese DJ; Foley J
    Oncol Res; 2013; 20(7):303-17. PubMed ID: 23879171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
    Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
    Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of transforming growth factor-alpha (TGF-alpha) in basal and hormone-stimulated growth by estradiol, prolactin and progesterone in human and rat mammary tumor cells: studies using TGF-alpha and EGF receptor antibodies.
    Ahmed SR; Badger B; Wright C; Manni A
    J Steroid Biochem Mol Biol; 1991 Jun; 38(6):687-93. PubMed ID: 2064983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with antibodies to the EGF receptor.
    Dean C; Modjtahedi H; Eccles S; Box G; Styles J
    Int J Cancer Suppl; 1994; 8():103-7. PubMed ID: 8194887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture.
    Huotari MA; Miettinen PJ; Palgi J; Koivisto T; Ustinov J; Harari D; Yarden Y; Otonkoski T
    Endocrinology; 2002 Nov; 143(11):4437-46. PubMed ID: 12399441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
    Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
    Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.